Sanofi has announced that its in-house developed drug, Amlitelimab, has successfully met all primary and secondary endpoints in the Phase III clinical trial, COAST 1, for the treatment of atopic dermatitis. Amlitelimab is a fully human monoclonal antibody that targets OX40L without depleting T cells. It is specifically designed for the treatment of immune and inflammatory diseases. Currently undergoing Phase III trials, Amlitelimab stands out as the sole OX40L antibody in this stage of development.

The COAST 1 study was designed to assess the efficacy and safety of Amlitelimab compared to a placebo in patients suffering from moderate-to-severe atopic dermatitis. The findings revealed that the Amlitelimab group outperformed the placebo group across several key indicators. Notably, the drug's efficacy showed a steady increase throughout the treatment period, with no signs of leveling off.

In terms of safety, the placebo group reported a higher frequency of common adverse events. In contrast, the incidence of treatment-emergent adverse events (TEAEs), serious adverse events, and TEAEs leading to treatment discontinuation were comparable between the Amlitelimab and placebo groups.

Furthermore, the upcoming 2025 China Pharma Decision Makers Summit is set to focus on the development trends and innovative breakthrough strategies for the pharmaceutical industry over the next decade.